Terminal · Institutions
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Catalys Pacific, LLC (CIK 2011385) reported $229.5M across 2 reported positions in its SEC 13F filing for 2026-06-30. Largest positions: MLYS ($213.2M, 92.94%), PHAT ($16.2M, 7.06%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | MLYS | Mineralys Therapeutics, Inc. | $213.2M | 92.94% | 7.9M | Hold |
| 2 | PHAT | Phathom Pharmaceuticals, Inc. | $16.2M | 7.06% | 1.5M | Hold |
Source: SEC Form 13F filings · as of 2026-06-30